TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9123740

Group type: EXPERIMENTAL
Intervention: 3 months of leuprolide acetate and flutamide (androgen deprivation)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Radical prostatectomy alone (control)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Nadir PSA ≤ 0.1 ng/mL
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Nadir PSA > 0.1 ng/mL
Number of subjects: 137
Study: 30154502

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Hysterectomy and Oophorectomy
Number of subjects: 5887

Group type: COMPARATOR
Intervention: Control (No Surgery)
Number of subjects: 5887
Study: 27539689

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14171

Group type: EXPERIMENTAL
Intervention: Long-term DAPT (≥30 days)
Number of subjects: 14171

Group type: EXPERIMENTAL
Intervention: Single antiplatelet therapy
Number of subjects: 14171

Group type: EXPERIMENTAL
Intervention: DAPT to monotherapy switch
Number of subjects: 14171

Group type: EXPERIMENTAL
Intervention: No antiplatelet therapy after PCI
Number of subjects: 14171

Group type: EXPERIMENTAL
Intervention: Stroke/systemic embolism rate
Number of subjects: 14171

Group type: EXPERIMENTAL
Intervention: Major bleeding events rate
Number of subjects: 14171
Study: 26634828

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 44
Study: 23540665

Group type: COMPARATOR
Intervention: Clopidogrel alone
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Clopidogrel combined with warfarin
Number of subjects: 88
Study: 17652615

Group type: EXPERIMENTAL
Intervention: Expert coaching in the All Stars prevention curriculum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no expert coaching)
Number of subjects: 0
Study: 17244833

Group type: EXPERIMENTAL
Intervention: Citalopram (20 to 40 mg/d)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Clinical Management
Number of subjects: 284
Study: 15061996

Group type: EXPERIMENTAL
Intervention: New method of arsenic trioxide administration (0.16 mg/kg divided into two doses, diluted in 250 ml of 5% glucose, given twice daily by intravenous infusion at 8 drops/min with a 2-3 hour interval)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Routine method of arsenic trioxide administration (0.16 mg/kg infused intravenously once a day for at most 2 hours)
Number of subjects: 96
Study: 11295002

Group type: EXPERIMENTAL
Intervention: TENS (transcutaneous electric nerve stimulation) applied on the contralesional side of the neck during the postural task (effective stimulation at threshold of perception)
Number of subjects: 22

Group type: COMPARATOR
Intervention: TENS (placebo stimulation at .01 x threshold of perception)
Number of subjects: 22
Study: 9588450

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study: 7979292

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 35
Study: 2543283

Group type: COMPARATOR
Intervention: R61837, given by intranasal spray six times a day, total dose 25 mg, starting 28 hours before virus challenge, continued for 4 days.
Number of subjects: 0

Group type: COMPARATOR
Intervention: R61837, total dose 36 mg, starting 4 hours before virus challenge, continued for 6 days.
Number of subjects: 0

Group type: COMPARATOR
Intervention: R61837, intranasal, doses of up to 15 mg/day, given shortly after onset of symptoms.
Number of subjects: 0
Study: 790411

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31432461

Group type: EXPERIMENTAL
Intervention: Paclitaxel micellar
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nab-paclitaxel
Number of subjects: 28
Study: 28283745

Group type: EXPERIMENTAL
Intervention: TF-TAVR
Number of subjects: 805

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 805
Study: 24666170

Group type: EXPERIMENTAL
Intervention: Plasma treatment (PlasmaDerm® VU‐2010) 3× per week for 8 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Plasma treatment (PlasmaDerm® VU‐2010)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard wound care
Number of subjects: 14
Study: 24273973

Group type: EXPERIMENTAL
Intervention: TAES (transcutaneous acupoint electrical stimulation)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IV group (intravenous injection of 2.5 mg droperidol)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: P6 group (Neiguan point injection of droperidol)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (2 mL 0.9% normal saline injection)
Number of subjects: 120
Study: 21733304

Group type: EXPERIMENTAL
Intervention: 600 mg Ca plus 2 mg Cu and 12 mg Zn
Number of subjects: 224

Group type: COMPARATOR
Intervention: 600 mg Ca plus maize starch placebo
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Zn supplementation with intakes < 8.0 mg/d
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Zn intakes ≥ 8.0 mg/d
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Mg intakes < 237 mg/d, Cu intakes < 0.9 mg/d, Zn intakes < 8.0 mg/d
Number of subjects: 224
Study: 18388160

Group type: EXPERIMENTAL
Intervention: Methotrexate, intra-articular betamethasone, ciclosporin/placebo-ciclosporin
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo-ciclosporin
Number of subjects: 130
Study: 17343005

Group type: EXPERIMENTAL
Intervention: Acupuncture following the principle of relieving depression and regulating mentality (RDRM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoxetine or Paroxetine (Western medicinal treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture following RDRM
Number of subjects: 0
Study: 15117040

Group type: EXPERIMENTAL
Intervention: Topical lomefloxacin 0.3%
Number of subjects: 41

Group type: COMPARATOR
Intervention: Topical ciprofloxacin 0.3%
Number of subjects: 41
Study: 11582899

Group type: EXPERIMENTAL
Intervention: Interpretive therapy
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Supportive therapy
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 139
Study: 9478327

Group type: EXPERIMENTAL
Intervention: Intramuscular progesterone (50 mg/day, Prontogest, AMSA, Italy)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Micronized vaginal progesterone (200 mg/day Esolut, Angelini, Italy)
Number of subjects: 250
Study: 8179132

Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation with propofol (bolus dose 18 mg over 5.4 s; lockout period 1 min)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Continuous propofol infusion (3.6 mg.kg‐1.h‐1)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Continuous infusion
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Indifferent
Number of subjects: 38
Study: 2966600

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with 0.125% bupivacaine and sufentanil 2 micrograms/ml
Number of subjects: 40

Group type: COMPARATOR
Intervention: Epidural analgesia with 0.25% bupivacaine and 0.125% bupivacaine infusion
Number of subjects: 40
Study: 30887868

Group type: EXPERIMENTAL
Intervention: 800 mg pine bark extract
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30633368

Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg, twice daily for 7 days)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Physiologically based pharmacokinetic model
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Consideration of hepatic CYP3A4 abundance and albumin concentration
Number of subjects: 1000
Study: 28692111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Placebo with ASA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ticagrelor and ASA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clopidogrel and ASA
Number of subjects: 40
Study: 26274827

Group type: EXPERIMENTAL
Intervention: Combined nutraceutical containing red yeast rice (Dif1Stat(®), including 5 mg monacolin K) and 610 mg PUFAs
Number of subjects: 107

Group type: COMPARATOR
Intervention: Phytosterols 1600 mg/die
Number of subjects: 107

Group type: COMPARATOR
Intervention: Comparison of combined nutraceutical vs phytosterols
Number of subjects: 107
Study: 23253886

Group type: EXPERIMENTAL
Intervention: Glutamine (0.4 g/kg/day of 20% solution of N(2)-L-alanyl-L-glutamine)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 64
Study: 21328143

Group type: EXPERIMENTAL
Intervention: Anticipated Regret (AR) manipulation
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Self-Efficacy (SE) manipulation
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Both AR and SE manipulations
Number of subjects: 414

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 414
Study: 19786383

Group type: EXPERIMENTAL
Intervention: MLCT oil (25-30 g daily for 8 weeks)
Number of subjects: 112

Group type: COMPARATOR
Intervention: LCT oil (25-30 g daily for 8 weeks)
Number of subjects: 112
Study: 18044273

Group type: EXPERIMENTAL
Intervention: Positive task experiences in information searching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative task experiences in information searching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial self-efficacy
Number of subjects: 0
Study: 15046230

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) for localized carcinoma of the prostate
Number of subjects: 38
Study: 11773988

Group type: EXPERIMENTAL
Intervention: Eprosartan
Number of subjects: 529

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 529
Study: 9551777

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (20 mg orally, twice daily for 10 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 8139472

Group type: EXPERIMENTAL
Intervention: High-tar cigarette
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-tar cigarette
Number of subjects: 10

Group type: COMPARATOR
Intervention: No smoking
Number of subjects: 10
Study: 2904183

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Salmeterol 100 micrograms
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Salmeterol 200 micrograms
Number of subjects: 8

Group type: COMPARATOR
Intervention: Salbutamol 200 micrograms
Number of subjects: 8
Study: 31531739

Group type: EXPERIMENTAL
Intervention: 3D printed models
Number of subjects: 27

Group type: COMPARATOR
Intervention: 3D virtual reality models
Number of subjects: 27
Study: 29658070

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBM) with low-level laser irradiation (LLLI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Endodontic treatment without PBM (Control group)
Number of subjects: 60
Study: 30587720

Group type: EXPERIMENTAL
Intervention: Robotic gastrectomy using da Vinci® Surgical System
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery
Number of subjects: 0
Study: 26354678

Group type: EXPERIMENTAL
Intervention: Reduced dose of zidovudine (400 mg)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Standard dose of zidovudine (600 mg)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Both doses of zidovudine
Number of subjects: 142
Study: 24473120

Group type: EXPERIMENTAL
Intervention: Animation and discussion about the importance of starting cardiopulmonary resuscitation upon recognizing an unresponsive patient.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified what intervention was used).
Number of subjects: 0
Study: 22619027

Group type: EXPERIMENTAL
Intervention: Low-dose hCG (200 IU per day) in late follicular phase
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard long protocol with gonadotropin administration (10,000 IU hCG for final maturation)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (gonadotropins)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Study group (low-dose hCG)
Number of subjects: 122
Study: 21051793

Group type: EXPERIMENTAL
Intervention: Fast Track intervention (10-year multi-component prevention program targeting antisocial behavior)
Number of subjects: 3274

Group type: EXPERIMENTAL
Intervention: Fast Track intervention
Number of subjects: 3274
Study: 18186581

Group type: EXPERIMENTAL
Intervention: Moxibustion treatment on Zhong‐Ji (CV‐3), Guan‐Yuan (CV‐4) and Qi‐Hai (CV‐6) for 10 days
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no moxibustion treatment)
Number of subjects: 39
Study: 15367100

Group type: EXPERIMENTAL
Intervention: Vitamin supplementation (folate/cyanocobalamin/pyridoxine)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Substance P
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Substance P-induced tissue plasminogen activator release
Number of subjects: 18
Study: 11911755

Group type: EXPERIMENTAL
Intervention: Intravenous nesiritide
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin
Number of subjects: 489

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study: 10340104

Group type: EXPERIMENTAL
Intervention: Androgen therapy for pubertal delay
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-term treatments to alter final adult height
Number of subjects: 0

Group type: COMPARATOR
Intervention: Growth hormone therapy
Number of subjects: 0
Study: 7603216

Group type: EXPERIMENTAL
Intervention: Enriched wafer (3.5 mg beta-carotene, 5.2 mg iron, 7.8 g fat)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Vegetable group (3.5 mg beta-carotene, 4.8 mg iron, 4.4 g fat)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control wafer (non-enriched wafer)
Number of subjects: 175
Study: 2196208

Group type: EXPERIMENTAL
Intervention: Sucralfate (4 g per day)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Ranitidine (300 mg per day)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sucralfate tablets (2 g per day)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 492891

Group type: EXPERIMENTAL
Intervention: Color film (intervention group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Black and white film (control group)
Number of subjects: 20
Study: 31764511

Group type: EXPERIMENTAL
Intervention: Oral 3000 IU/d retinol for 8 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral 6000 IU/d retinol for 8 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 22
Study: 30910353

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Long‐acting betamethasone
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Long‐acting betamethasone and Dexamethasone
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Corticosteroids (Dexamethasone and Long‐acting betamethasone)
Number of subjects: 197
Study: 28320537

Group type: COMPARATOR
Intervention: 400 mg ibuprofen acid (Advil)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 512 mg ibuprofen sodium dihydrate (Advil Sodium)
Number of subjects: 41
Study: 26398817

Group type: EXPERIMENTAL
Intervention: LLLT associated with aerobic plus resistance training
Number of subjects: 2
Study: 23194830

Group type: EXPERIMENTAL
Intervention: Active treatment (rTMS applied to the DLPFC; 10 sessions; 1 session a day; frequency = 10 Hz; intensity = 110% of motor threshold)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment (sham coil)
Number of subjects: 20
Study: 21122851

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10mg/d
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: allopurinol 300mg/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 19246724

Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg oral dose
Number of subjects: 32
Study: 17188883

Group type: EXPERIMENTAL
Intervention: Aminophylline (5mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 30
Study: 14658999

Group type: EXPERIMENTAL
Intervention: Training (combined strength and endurance exercises) four times per week, two times supervised and two times at home
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 77
Study: 11701404

Group type: EXPERIMENTAL
Intervention: Topical 20% azelaic acid cream plus oral minocycline
Number of subjects: 85

Group type: COMPARATOR
Intervention: Oral isotretinoin
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Topical 20% azelaic acid cream (maintenance therapy)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Oral isotretinoin (control during maintenance phase)
Number of subjects: 85
Study: 9331000

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (2-16 mg, single and repeated once-daily doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7936333

Group type: EXPERIMENTAL
Intervention: Intravenous propafenone
Number of subjects: 54

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 54
Study: 3569450

Group type: EXPERIMENTAL
Intervention: Low tar cigarette
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-to-middle tar cigarette
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Middle tar cigarette
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Puff work
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Puff resistance
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Puff work and puff resistance correlation
Number of subjects: 10
Study: 29705177

Group type: EXPERIMENTAL
Intervention: Exercise group (n=45): Three daily sets of single-leg standing (1 min/leg/set) and squatting (5-6 repetitions/set).
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Vitamin D group (n=42): Supplementation of 1000 IU/day of vitamin D.
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Exercise and vitamin D group (n=43): Combination of exercise and vitamin D supplementation.
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group: Not explicitly mentioned in the abstract.
Number of subjects: 148
Study: 27593436

Group type: EXPERIMENTAL
Intervention: SAQ training (12-week intervention, 2 days/week)
Number of subjects: 35
Study: 25060545

Group type: EXPERIMENTAL
Intervention: 80% FiO2
Number of subjects: 81

Group type: COMPARATOR
Intervention: 30% FiO2
Number of subjects: 81
Study: 15662516

Group type: EXPERIMENTAL
Intervention: Anal dilatation
Number of subjects: 60

Group type: COMPARATOR
Intervention: No anal dilatation (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 12131107

Group type: EXPERIMENTAL
Intervention: PSI guidance
Number of subjects: 306

Group type: COMPARATOR
Intervention: Standard practice control
Number of subjects: 306

Group type: COMPARATOR
Intervention: Historic control
Number of subjects: 306
Study: 9925702

Group type: EXPERIMENTAL
Intervention: Endoscopic evaluation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS) evaluation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: EUS evaluation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sclerotherapy
Number of subjects: 60
Study: 7503183

Group type: EXPERIMENTAL
Intervention: Continuous combined replacement therapy (group B): 2 mg of estradiol, 1 mg of estriol, and 1 mg of norethisterone acetate daily for 12 days per month.
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sequential estrogen-progestogen replacement therapy (group A): 2 mg of estradiol valerate daily and 5 mg of medroxyprogesterone acetate daily for 12 days per month.
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 140
Study: 2196946

Group type: EXPERIMENTAL
Intervention: Relaxation therapy (trained for 8 weeks, one hour a week, continued exercising twice daily for one year)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Non-specific counselling (same attendance schedule, no training, just sit and relax twice a day)
Number of subjects: 35
Study: 7381637

Group type: EXPERIMENTAL
Intervention: Phenobarbital 5 mg/kg in a single daily dose
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo with riboflavin tracer
Number of subjects: 79
Study: 30477009

Group type: EXPERIMENTAL
Intervention: Triplet-based induction therapy with Carfilzomib, Lenalidomide, and Dexamethasone followed by Lenalidomide maintenance therapy
Number of subjects: 0
Study: 28292764

Group type: EXPERIMENTAL
Intervention: Pigs for Peace (PFP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rabbits for Resilience (RFR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed control group
Number of subjects: 0
Study: 25427877

Group type: EXPERIMENTAL
Intervention: Usual cessation support plus a retail voucher to the value of NZ$25 for each 'abstinent from smoking' week for 8 weeks (voucher)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Usual cessation support plus product to the value of NZ$25 for each 'abstinent from smoking' week for 8 weeks (product)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual cessation support (control)
Number of subjects: 24
Study: 23295472

Group type: EXPERIMENTAL
Intervention: Low-frequency transcutaneous electrical nerve stimulation (LF-TENS) for 30 minutes daily for 10 days
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham TENS for 30 minutes daily for 10 days
Number of subjects: 33
Study: 21592295

Group type: EXPERIMENTAL
Intervention: Silodosin 4 mg twice daily
Number of subjects: 209

Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg once daily
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Silodosin
Number of subjects: 209

Group type: COMPARATOR
Intervention: Tamsulosin
Number of subjects: 209
Study: 18089891

Group type: EXPERIMENTAL
Intervention: DAG oil
Number of subjects: 25

Group type: COMPARATOR
Intervention: TAG oil
Number of subjects: 25